Jennifer Zachary - Merck President
| MRK Stock | EUR 155.35 1.45 0.94% |
President
Ms. Jennifer Zachary is Executive Vice President, General Counsel of the Company, effective April 16, 2018. Zachary is currently a partner at Covington Burling in the firm food, drug, and device practice group where she advises a wide range of manufacturers and industry trade associations on FDA requirements for the development, manufacture, and distribution of prescription and overthecounter drugs, biologics, and medical devices. Zachary began her career in FDA Office of Chief Counsel, where she served as an Associate Chief Counsel for Enforcement from 2005 to 2011. Zachary also served as a Special Assistant U.S. Attorney in the Civil Division of the U.S. Attorney Office for the District of Columbia. since 2020.
| Age | 41 |
| Tenure | 4 years |
| Phone | 49 6151 72 0 |
| Web | https://www.merckgroup.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.0656 % which means that it generated a profit of $0.0656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1422 %, meaning that it generated $0.1422 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | PRESIDENT Age | ||
| Andrew Peyton | Superior Plus Corp | 55 | |
Management Performance
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Matthias Heinzel, CEO Board | ||
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
| Gerhard Schmitz, Head Accounting | ||
| Christine Seidman, Independent Director | ||
| Kathy Warden, Independent Director | ||
| Constantin Fest, Head Relations | ||
| Paul Rothman, Independent Director | ||
| Mary Coe, Independent Director | ||
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
| Peter Guenter, CEO Board | ||
| Barbara Weiland, Chief Officer | ||
| Belen MD, Chair CEO | ||
| Marcus Kuhnert, CFO Board | ||
| Peter Wendell, Independent Director | ||
| Friederike Rotsch, Group Compliance | ||
| Leslie Brun, Lead Independent Director | ||
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
| Inge Thulin, Independent Director | ||
| Dirk Toepfer, Chief Officer | ||
| Pamela Craig, Independent Director | ||
| Patricia Russo, Independent Director | ||
| Franklin Clyburn, Executive Vice President Chief Commercial Officer | ||
| Rita Karachun, Senior Vice President - Finance, Global Controller | ||
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
| Kai Beckmann, CEO Board | ||
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Executive Vice President, Chief Marketing Officer | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.14 | |||
| Return On Asset | 0.0656 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 87.36 B | |||
| Shares Outstanding | 129.24 M | |||
| Shares Owned By Institutions | 60.26 % | |||
| Price To Earning | 36.46 X | |||
| Price To Book | 2.77 X | |||
| Price To Sales | 3.80 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |